Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in therapeutics that target toxic soluble amyloid beta oligomers (ABOs) for treating Alzheimer’s disease (AD), announced that it has entered into a collaboration agreement with Lonza under which Lonza will manufacture sabirnetug (ACU193), a monoclonal antibody (mAb) that targets toxic soluble ABOs. The mAb is currently in clinical development for treating AD. Source: Biopharm International 4/4/2024